ALKS Alkermes plc.
Price Chart
Executive Summary
Alkermes announced positive topline results from the REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia (IH), meeting all primary and key secondary endpoints with high statistical significance (p<0.0001). The company plans to file an sNDA with the FDA by end of 2026, but a prior settlement agreement bars marketing LUMRYZ for IH before March 1, 2028, even if approved. This is a clear clinical win that expands LUMRYZ's addressable market into a rare disease affecting ~40,000 U.S. patients, though commercial upside is delayed by the marketing restriction.
Actionable Insight
The Phase 3 success removes clinical risk for LUMRYZ in IH, but the 2028 marketing restriction caps near-term revenue upside. Watch for sNDA filing progress and FDA acceptance in H2 2026; any update on the settlement agreement timeline could be a catalyst. The stock may gap up on the clinical data but the delayed commercial launch limits the magnitude.
Key Facts
- LUMRYZ met the primary endpoint (ESS, p<0.0001) and all key secondary endpoints (PGI-C, IHSS, both p<0.0001) in the REVITALYZ Phase 3 study for idiopathic hypersomnia.
- Safety profile consistent with known LUMRYZ data; no new safety signals observed.
- Alkermes plans to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026.
- A prior settlement and license agreement prohibits marketing LUMRYZ for IH before March 1, 2028, even if FDA approval is granted earlier.
- Idiopathic hypersomnia affects an estimated 40,000 people in the U.S., representing a new, addressable rare disease market for LUMRYZ.
Financial Impact
No financial figures provided in the filing. LUMRYZ is already approved for narcolepsy; IH label expansion opens a new market of ~40,000 U.S. patients, but commercialization is barred until March 1, 2028.
Risk Factors
- Marketing restriction until March 1, 2028 limits near-term revenue from IH even if FDA approves.
- FDA may not accept or approve the sNDA; regulatory risk remains.
- Competition from other IH treatments could emerge before 2028.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218150 |
| Document: alks-20260512.htm | 0001193125-26-218150 |
| Document: 0001193125-26-218150-index-headers.html | 0001193125-26-218150 |
| Document: 0001193125-26-218150-index.html | 0001193125-26-218150 |
| Document: 0001193125-26-218150.txt | 0001193125-26-218150 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
today
|
8-K
| — | awaiting T+5 | — | — |
|
May 13, 2026
7d ago
|
DEFA14A
| — | awaiting T+5 | — | — |
|
May 12, 2026
8d ago
|
8-K
| $38.26 $37.19 | ▼ −2.79% | ▼ −2.87% | $36.98 (−3.34%) |
|
May 5, 2026
15d ago
|
8-K
| $36.23 $38.26 | ▲ +5.60% | ▲ +3.62% | $36.98 (+2.08%) |
|
May 1, 2026
19d ago
|
Insider Cluster
| $33.26 $35.40 | ▲ +6.44% | ▲ +4.10% | $36.98 (+11.19%) |
|
Mar 2, 2026
11w ago
|
Insider Cluster
| $30.24 $28.45 | ▼ −5.92% | ▼ −4.71% | $36.98 (+22.30%) |
|
Feb 25, 2026
12w ago
|
8-K
| $31.03 $29.16 | ▼ −6.03% | ▼ −4.93% | $36.98 (+19.19%) |
|
Feb 25, 2026
12w ago
|
8-K
| $31.03 $29.16 | ▼ −6.03% | ▼ −4.93% | $36.98 (+19.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access